Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07456371 | PIC1 Injection Therapy for Relapsed/Refractory B-NHL | PHASE1 | RECRUITING | 18 | — | — | Mar 1, 2026 | Feb 1, 2029 | Mar 6, 2026 | 1 | China |
Types, frequency and severity of adverse events.
| Arm | Type | Description |
|---|---|---|
| PIC1 Injection | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PIC1 Injection | BIOLOGICAL | Three dose groups (1.0×10\^9 TU, 2.0×10\^9 TU, 4.0×10\^9 TU) were set up, starting from the low dose group climbing to explore the safe and effective dose. |
Inclusion Criteria: * The patient (or their legally authorized representative) has voluntarily agreed to participate in this clinical trial and has signed the Informed Consent Form (ICF), indicating full understanding of the study's objectives and procedures. * Aged 18 to 75 years, regardless of ge...